Radiopharm Theranostics Limited Depositary Receipt is the U.S.-traded depositary receipt for Radiopharm Theranostics Limited, a clinical-stage biopharmaceutical company focused on radiopharmaceutical products for diagnostic imaging and targeted therapy. The company develops oncology-focused technologies designed to address areas of high unmet medical need, with programs spanning both pre-clinical and clinical stages of development. Its current pipeline includes diagnostic and therapeutic candidates built around radiopharmaceutical platforms for cancer targeting, reflecting a business centered on precision medicine and molecular imaging. Radiopharm Theranostics Limited serves researchers, clinicians, and healthcare stakeholders working in cancer diagnosis and treatment, and its depositary receipt provides a market-facing representation of the company’s ordinary shares for international investors.
Website62 Lygon Street
Carlton, VIC, 3053
Australia
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint Meeting with FDA planned on October 1st to align on RAD101Phase 3 pivotal trial protocol Brain Metastases Imaging has ~$600 million total addressable market, and there are no currently approved PET products SYDNEY, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on
Positive safety and favourable biodistribution seen in all subjects dosed Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake Data support the targeting potential of RAD301 and continuation of its clinical development SYDNEY, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceutical
Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated clinical proof-of-concept with positive safety and biodistribution SYDNEY, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for ar
Investors talking about RADX also mention
What share of all stock conversation is about RADX?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% new | 0% 0 | 0% 0 | 0% 0 |
Of the messages about RADX that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | 66.67% +6.67 | 39.13% -21.21 | 73.05% -7.18 | ||
| Bearish | — | 33.33% -6.67 | 60.87% +21.21 | 26.95% +7.18 |
Of the messages about RADX that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 100% | 92.31% | 56.81% | ||
| Technical Analysis | — | 0% | 7.69% | 34.17% | ||
| Analysts | — | 0% | 0% | 5.5% | ||
| Controversies | — | 0% | 0% | 0.32% | ||
| Earnings | — | 0% | 0% | 0% | ||
| Macro | — | 0% | 0% | 3.2% |
Of the messages about RADX, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 100% | 100% | 68.92% | 47.46% | ||
| Newcomers | 0% | 0% | 31.08% | 52.54% |